
The Future of Kidney Transplant Monitoring: Moving Beyond Biopsies - Sara Barrington, CEO of Verici Dx
Notas do episódio
In this episode of Diagnosing Dx, I’m joined by Sara Barrington, CEO at Verici Dx.
Sara explains how Verici Dx is tackling one of the biggest unresolved problems in kidney transplant care: helping clinicians monitor patients more precisely after transplant without relying so heavily on biopsies and legacy testing.
We explore why balancing rejection risk against unnecessary immunosuppression is so difficult, and how better molecular insight could support earlier, more accurate decisions.
We also discuss Verici Dx’s RNA sequencing and AI-driven approach, the decision to license one test to Thermo Fisher while commercialising another directly, and what it means to build a diagnostics company that went public from day one. This is a practical conversation about transplant medicine, commercialization, and better clinical decision-making.
Key takeaways:
🔹 Why post-transplant monitoring still relies too heavily on invasive and outdated methods
🔹 How RNA sequencing and AI could improve rejection prediction and patient management
🔹 Why reducing unnecessary immunosuppression is such an important clinical goal
🔹 How Verici Dx built an end-to-end transplant testing strategy across pre- and post-transplant care
🔹 What licensing, reimbursement, and public-market strategy look like in a real diagnostics company
Guest:
Sara Barrington
CEO at Verici Dx
LinkedIn: https://www.linkedin.com/in/sara-barrington-06926382/
Host:
David Filby
LinkedIn: https://www.linkedin.com/in/davidfilby/
🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.